Education
About Us
Working with TipRanks
Follow Us
Zevra Therapeutics (ZVRA)
NASDAQ:ZVRA
Total Valuation
Zevra Therapeutics has a market cap or net worth of $581.24M. The enterprise value is $558.15M.
Market Cap$581.24M
Enterprise Value$558.15M
Share Statistics
Zevra Therapeutics has 58,711,582 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding58,711,582
Owned by Insiders1.37%
Owned by Institutions9.24%
Financial Efficiency
Zevra Therapeutics’s return on equity (ROE) is 0.54 and return on invested capital (ROIC) is -1.65%.
Return on Equity (ROE)0.54
Return on Assets (ROA)0.29
Return on Invested Capital (ROIC)-1.65%
Return on Capital Employed (ROCE)-0.02
Revenue Per Employee1.80M
Profits Per Employee1.41M
Employee Count59
Asset Turnover0.37
Inventory Turnover11.80
Valuation Ratios
The current PE Ratio of Zevra Therapeutics is 6.0. Zevra Therapeutics’s PEG ratio is -0.04.
PE Ratio6.0
PS Ratio4.65
PB Ratio3.20
Price to Fair Value3.20
Price to FCF-203.69
Price to Operating Cash Flow-342.67
PEG Ratio-0.04
Income Statement
In the last 12 months, Zevra Therapeutics had revenue of 106.47M and earned 83.23M in profits. Earnings per share was 1.40.
Revenue106.47M
Gross Profit85.93M
Operating Income-4.23M
Pretax Income86.68M
Net Income83.23M
EBITDA-179.00K
Earnings Per Share (EPS)1.40
Cash Flow
In the last 12 months, operating cash flow was -1.60M and capital expenditures -835.00K, giving a free cash flow of -2.43M billion.
Operating Cash Flow-1.60M
Free Cash Flow-2.43M
Free Cash Flow per Share-0.04
Dividends & Yields
Zevra Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.65
52-Week Price Change24.22%
50-Day Moving Average8.98
200-Day Moving Average9.47
Relative Strength Index (RSI)58.37
Average Volume (3m)2.44M
Important Dates
Zevra Therapeutics upcoming earnings date is May 19, 2026, TBA (Confirmed).
Last Earnings DateMar 9, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
Zevra Therapeutics as a current ratio of 5.68, with Debt / Equity ratio of 40.87%
Current Ratio5.68
Quick Ratio5.63
Debt to Market Cap0.13
Net Debt to EBITDA-4.47
Interest Coverage Ratio-0.53
Taxes
In the past 12 months, Zevra Therapeutics has paid 3.45M in taxes.
Income Tax3.45M
Effective Tax Rate0.04
Enterprise Valuation
Zevra Therapeutics EV to EBITDA ratio is -2.77K, with an EV/FCF ratio of -204.02.
EV to Sales4.66
EV to EBITDA-2.77K
EV to Free Cash Flow-204.02
EV to Operating Cash Flow-310.63
Balance Sheet
Zevra Therapeutics has $191.01M in cash and marketable securities with $63.21M in debt, giving a net cash position of $127.81M billion.
Cash & Marketable Securities$191.01M
Total Debt$63.21M
Net Cash$127.81M
Net Cash Per Share$2.18
Tangible Book Value Per Share$2.60
Margins
Gross margin is 80.71%, with operating margin of -3.98%, and net profit margin of 78.17%.
Gross Margin80.71%
Operating Margin-3.98%
Pretax Margin81.41%
Net Profit Margin78.17%
EBITDA Margin-0.17%
EBIT Margin-3.98%
Analyst Forecast
The average price target for Zevra Therapeutics is $23.71, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$23.71
Price Target Upside140.22% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast240.47%
EPS Growth Forecast―